

Becoming the leading Company in research, manufacture and distribution of pharmaceuticals and supplements

STOCK INFORMATION

(mai: JSP)


Share price (Sep 12, 2023): Historical price:	THB 2.44		
52-week high 52-week low	THB 4.50 THB 2.28		
No. of shares:	474.49 m		
Par value:	THB 0.50		
Market Capitalization: Value Trade/Day:	THB 1,157.76 m THB 6.38 m		
Free float:	26.37%		
Foreign ownership:	0.02%		
Foreign limit:	49.00%		

MAJOR SHAREHOLDERS

Suphap Group Co., Ltd.	30.11
Pissanu Daengprasert	6.59
Jintana Santipisud	6.59
Sorasit Daengprasert	6.59
Sittichai Daengprasert	6.51
Jirada Daengprasert	6.28

(%)


1H/2023 Operating Revenue **Breakdown by Business**



BUSINESS INSIGHT


- In 1H/2023, JSP displays strong revenue growth of Baht 240.6 million (+31.9% YoY) and gross profit of Baht 53.5 million (+23.2% YoY) mainly due to an increase in revenue from 1) Recovery in orders from OEM especially from dietary supplements and conventional medicine 2) Maintaining leading position in TV Shopping channel for own Suphap Osot brand 3) Additional revenue from new investment in the Hemodialysis business
- The Company continues to seek new investment opportunities to increase customer base while ensuring synergy between the group. In 1H/2023 the Company has acquired 52% of Grace Water Med focused on kidney patients. This acquisition will benefit the Company by obtaining a new source of revenue (hemodialysis solution), increasing trading of medical equipment supported by JSP related to kidney patients, and developing cosmetics and supplement for this new sector, supported by Caresutic. With the ageing society trend, this customer segment will display continuous growth opportunities.
- In addition, the Company have introduced a new service for Caresutic to capture a high growth industry: Pet. After COVID-19, the pet industry have been gaining importance imposing opportunities for growth. The Pet skincare and supplement industry is forecasted to grow at 7.6% CAGR until the end of 2028. As a result, the Company have introduced a new service of OEM for Pet Supplement and Cosmetic which have received strong positive feedback from the market in Q2/2023.
- In 2H/2023, JSP maintains the target to capture a 20-30% growth rate. The Company has outlined several strategic initiatives including 1) increasing the production capacity of hemodialysis solutions by 2 times at GWM 2) continuing to host open house events to capture new customer base, especially for PET, which the company target revenue recognition in Q1/24 3) increasing coverage of home shopping channels and maintain leadership position under "Suphap-Osot" brand 4) recognizing revenue from cosmetics for human in Q4/23, which is a new category at Caresutic.

Overall 1H/2023 Performance



Operating revenue increased mainly due to:

- More orders from customers for dietary supplements and conventional medicine
- The effectiveness of the sales promotion campaign
- Installation of purified water system performed by a subsidiary



Increased revenue from sales

promotion expenses with TV

revenue in accordance with

The Company reported

Direct as a deduction to

TERS 15 standards

- Increased revenue from sales
 - Decrease in advertising and promotion expenses from billboards as well as agent fees due to the Company's sales employees are capable of managing customers themselves


-4.5%

(10.9)

1H/23

NPM

Q2/2023 Investor Note



Q2/2023 Investor Note



*Note: Annualized from quarterly figures

Total Capacity

Product Type	Product Form		Additional Capacity in 2023 2023		Utilization of 1H/2023	% Utilization
	Liquid	Million m ³	+1,872.0	2,246.4	209.3	9.3%
-	Hormone	Million Pills	+25.3	212.5	2.2	1.0%
Pharmaceuticals	Soft Gelatin Capsule	Million Pills	-	86.5	0.0	0.0%
	Cream	Million g	-	62.4	0.6	1.0%
	Tablet	Million Pills	-	76.8	28.6	37.3%
Supplements (for Humans and	Hard Gelatin Capsule	Million Pills	+121.1	144.5	3.0	2.1%
Pets)	Soft Gelatin Capsule	Million Pills	+89.4	201.8	61.4	30.4%
	Powder	Million g	-	78.6	2.4	3.1%
Cosmetics	Gel	Million m ³	-	393.1	22.0	5.6%
	Tablet	Million Pills	-	81.6	6.5	8.0%
Herbal products	Hard Gelatin Capsule	Million Pills	+99.1	239.6	9.2	3.8%
	Liquid	Million m ³	-	404.4	0.0	0.0%
	Ointments	Million g	-	112.3	1.6	1.4%
Hemodialysis (52%)	A-B Solution	Gallon/ month	+120,000	240,000	120,000	100%
Medis (28.6%)	Vending Machine	No .of Machines	+44	44	44	100%

Note : *As its current utilization rate is high, the company is expanding its production capacity.

Q2/2023 Investor Note

Strategic Directions



Mainly from Black Sesame Oil and Rice Bran Oil via TV direct

Innovative pharmaceuticals and supplements product manufacturer

- Continuous R&D and innovative product launch, such as soft gelatin capsule, and chewable soft gelatin capsule
- Expand to pet products

- Recognized revenue from new production facilities fully operational
- Capacity expansion of liquid will be operated at full capacity with backlog of 2.0 mil bottles
- Acquire business for developing innovative products, and expanding distribution channels

202	25	
CAGR -	+30%	
2023-2	2025	1
alexand a	SE -	All a

Leading pharmaceuticals and supplements OEM in Thailand

~

- Thailand's leading pharmaceutical and supplement OEM for Human and Pets
 - **Expanding customer base** to drive more growth
- Continuous R&D and innovative product to increase choices for customers
- **Capacity expansion** for support customer demand

2027

Thailand's leading innovative pharmaceutical and supplement brand

- Thailand's well-known pharmaceutical and supplement brand for Human and Pets
- Continuous focus on organic growth from new facility expansion and product development to support customer demand
- Considering seeking a strategic partner and M&A deal with companies that have synergies with JSP's business to drive more growth



Strategies					
"Becoming the leading company in research, manufacture and distribution of pharmaceuticals and supplements"					
	Innovation for Growth	2 Elevate Own-Brand Business	B Strengthen OEM Business	4 Capture Opportunity	5 Expand to CLMV
v	 Continuous R&D for innovative products Current innovation for growth: Pet supplement product Chewable and Vegetable soft gelatin capsule Plant-based protein 	 Obtain <i>new</i> <i>product licenses</i> <i>Introduce</i> differentiated <i>own-brand products</i> <i>Launch wide-scale</i> <i>marketing</i> to strengthen brand awareness 	 Leverage current strengths and focus on <i>acquiring new</i> <i>major partner</i> Adding <i>new</i> <i>innovative</i> <i>products</i> to enhance customer's choice 	 Invest in small- and-medium-size healthcare companies with high growth potential 	 Acquire new licenses in each country Expand distribution of products through local distributor

supplement ✓ Herbal Soft gelatin

capsule